Patents by Inventor Kirk Lang Olson

Kirk Lang Olson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR MODULATING FGF ACTIVITY
    Publication number: 20240173311
    Abstract: The invention features compounds and a method of treating an injury or a disease e.g., stroke, congenital hypogonadotropic hypogonadism, and viral infection, using the compounds. Also featured is a pharmaceutical composition containing one or more of the compounds, and a method of increasing spermatogenesis using the compounds.
    Type: Application
    Filed: February 11, 2022
    Publication date: May 30, 2024
    Inventors: Seth P. FINKLESTEIN, Gregory D. CUNY, Renato SKERLJ, Soumya RAY, Stephen Douglas BARRETT, Kirk Lang OLSON
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY
    Publication number: 20240174631
    Abstract: The invention features compounds which modulate FGF activity, e.g., by enhancing the binding between FGF-2 and its receptors, e.g., FGF-R1. Also featured is a pharmaceutical composition containing one or more of the compounds, a method of treating an injury or a disease e.g., stroke, congenital hypogonadotropic hypogonadism, and viral infection, and a method of increasing spermatogenesis using the pharmaceutical composition.
    Type: Application
    Filed: February 11, 2022
    Publication date: May 30, 2024
    Inventors: Seth P. FINKLESTEIN, Gregory D. CUNY, Renato SKERLJ, Soumya RAY, Stephen Douglas BARRETT, Kirk Lang OLSON, Fred Lawrence CISKE, Paige Elizabeth HEIPLE, Melissa Christine HOLT, James Bernard KRAMER
  • Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin Dmediated diseases
    Patent number: 9126973
    Abstract: Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D2 mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: September 8, 2015
    Assignee: CAYMAN CHEMICAL COMPANY, INCORPORATED
    Inventors: Gregory W. Endres, Pil Heui Lee, Kirk Lang Olson, James Bernard Kramer, Fred Lawrence Ciske, Stephen Douglas Barrett
  • MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES
    Publication number: 20150099748
    Abstract: Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D2 mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).
    Type: Application
    Filed: September 29, 2014
    Publication date: April 9, 2015
    Inventors: Gregory W. Endres, Pil Heui Lee, Kirk Lang Olson, James Bernard Kramer, Fred Lawrence Ciske, Stephen Douglas Barrett
  • Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
    Patent number: 8536185
    Abstract: Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D2 mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: September 17, 2013
    Assignee: Cayman Chemical Company, Incorporated
    Inventors: Gregory W. Endres, Pil Heui Lee, Kirk Lang Olson, James Bernard Kramer, Fred Lawrence Ciske, Stephen Douglas Barrett
  • Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
    Patent number: 8450326
    Abstract: Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D2 mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: May 28, 2013
    Assignee: Cayman Chemical Company, Incorporated
    Inventors: Gregory W. Endres, Pil Heui Lee, Kirk Lang Olson, James Bernard Kramer, Fred Lawrence Ciske, Stephen Douglas Barrett
  • MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES
    Publication number: 20100075990
    Abstract: Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D2 mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).
    Type: Application
    Filed: September 22, 2009
    Publication date: March 25, 2010
    Applicant: CAYMAN CHEMICAL COMPANY
    Inventors: Gregory W. Endres, Pil Heui Lee, Kirk Lang Olson, James Bernard Kramer, Fred Lawrence Ciske, Stephen Douglas Barrett